News & Events
DATE2024.03.22
VIEWS246
'BIOPLUS - INTERPHEX KOREA 2024 (hereinafter referred to as BIX 2024)', Korea's largest global biotechnology and pharmaceutical convention, is scheduled to take place at COEX for three days from July 10 to 12, 2024.
With the main theme of 'World's Most Tangible Bio-healthcare Convention', BIX 2024 encompasses exhibitions, conferences, open innovation, partnering, networking receptions, and docent programs, representing the bio-pharmaceutical industry.
Aligned with the growing global interest in the bio-pharmaceutical market, BIX 2024 serves as the optimal business platform for both Korean and international bio-pharmaceutical industries, offering valuable insights into business strategies, technologies, and market trends of companies worldwide. The event aims to facilitate networking opportunities, fostering collaboration between domestic and foreign entities to propel the industry growth.
The theme of this year's conference, 'Embrace All Possibilities', underscores the importance for biotechnology and pharmaceutical companies to seek new opportunities through diverse cooperative relationships, fostering innovation along the way. It emphasizes that 'cooperation' is the most important opportunity for advancement in these sectors.
The conference features approximately 130 Korean and international experts as speakers, including Professor Richard D. Braatz, a professor in the Department of Chemical Engineering at MIT's College of Engineering. More than 20 specialized sessions cover trendy topics in the global biotech industry, encompassing policy regulations, latest technology, investment accounting, and business strategy. Attendees can expect to gain new insights and explore collaboration models.
The exhibition, a flagship program of BIX, garnered high satisfaction among participating companies. With a remarkable 60% re-participation (on-site rebooking rate) from the event held in July the previous year, there was significant interest from industry-leading companies for participation in this year’s event.
The upcoming exhibition, set to surpass last year's scale, will host around 250 companies spanning the entire biopharmaceutical industry, including R&D, manufacturing processes, logistics, packaging, digital healthcare, and advanced bio, with a total of 450 booths. These include categories such as digital healthcare, biotechnology R&D, experimental equipment and analysis, advanced bio (green·white), manufacturing and facilities, service (clinical·non-clinical consulting), cold chain packaging·logistics, and representation from hospitals, universities, and public institutions. Of note is the special hall showcasing emerging bio-related trends like CMO·CDMO, bio materials, parts, and equipment, digital healthcare, and cold chain logistics. Visitors will have the opportunity to engage directly with industry experts at each booth, discussing the latest technologies and solutions in the biotechnology and pharmaceutical production.
The deadline for exhibitors at BIX 2024 is April 10. With roughly 80% of booths already confirmed, prompt application is required for participation. Those interested in exhibiting or sponsorship should reach out to the BIX Secretariat. Additionally, pre-registration for visitors to access all BIX events, including exhibitions and conferences, is scheduled to open in mid-April. Detailed information about the event can be found on the official website.
Meanwhile, BIX is an event hosted by the Korea Biotechnology Industry Organization (KoreaBio) and supervised by Reed Exhibitions Korea (RX KOREA), celebrating its 5th anniversary this year. The previous BIX 2023 event attracted approximately 8,800 Korean and international attendees, with over 190 companies and institutions from 30 different countries, including multinational pharmaceutical firms and local biotech companies, occupying 412 booths. This solidified BIX’s position as Korea's largest global biopharmaceutical convention, both in reputation and scale.
by THE BIO (https://www.thebionews.net)
